aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Cadex Genomics, founded with a mission to enhance the lives of cancer patients, focuses on developing innovative molecular diagnostic tests. The company specializes in liquid-based technology to provide personalized insights into cancer therapy responses. Their flagship product, Alibrex®, is a blood test designed to identify real-time disease progression in stage IV cancer patients, aiming for availability by late 2024 or early 2025. Cadex Genomics seeks to revolutionize cancer treatment by significantly reducing the time it takes for oncologists to evaluate treatment efficacy.
Notable figures affiliated with Cadex Genomics include experts in molecular diagnostics and oncology, although specific names are not provided. The company has garnered attention for its cutting-edge approach to cancer diagnostics, combining proven DNA measurement techniques with advanced technology to improve accuracy and sensitivity. By offering timely and precise diagnostic tools, Cadex Genomics aims to make a substantial impact on cancer treatment outcomes and patient quality of life.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Diagnostic Tests
Technology
Biotech
Tags
Healthtech
Model Types
Data Information, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
United States
When was Cadex Genomics founded?
Cadex Genomics was founded in 2018.
Where is Cadex Genomics’s headquarters located?
Cadex Genomics’s headquarters is located in Redwood City, CA, US.
When was Cadex Genomics’s last funding round?
Cadex Genomics’s most recent funding round was for $1.5M (USD) in February 2019.
How many employees does Cadex Genomics have?
Cadex Genomics has 7 employees as of Feb 4, 2024.
How much has Cadex Genomics raised to-date?
As of July 05, 2023, Cadex Genomics has raised a total of $1.5M (USD) since Feb 15, 2019.
Add Comparison
Total Raised to Date
$1.5M
USD
Last Update Feb 15, 2019
Last Deal Details
$1.5M
USD
Feb 15, 2019
Seed
Total Employees Over Time
7
As of Feb 2024
Cadex Genomics Address
541 Jefferson Avenue
Suite 100
Redwood City,
California
94063
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts